Andrew Bellinger, MD, PhDChief Scientific Officer at Verve Therapeutics
Agenda Sessions
In Vivo Gene Editing for Atherosclerotic Cardiovascular Disease
, 8:45amView Session
This site is part of the Informa Connect Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
In Vivo Gene Editing for Atherosclerotic Cardiovascular Disease